Avacta Therapeutics (AIM: AVCT) names Richard Hughes chairman as Shaun Chilton steps back

Avacta Therapeutics (AIM: AVCT) has announced a leadership transition at the top of its board, confirming that non-executive director Richard Hughes will become non-executive chairman immediately after the company’s annual general meeting on 22 June 2026. Richard Hughes succeeds Shaun Chilton, who steps down from the board but stays on as an adviser to the chief executive officer and the wider director group. Alongside the handover, Avacta Therapeutics said it is adding a deputy chairman with global biotechnology experience to deepen board capability as the clinical-stage oncology company pushes its pre|CISION drug conjugate candidates toward later development and pursues potential pharmaceutical partnerships. The change lands with AVCT shares trading near the upper end of a 52-week range that has swung from roughly 26p to 92p, a recovery that gives the board reshuffle a very different backdrop than the one Shaun Chilton inherited. For a company that has spent two years converting itself from a diagnostics-plus-therapeutics conglomerate into a focused oncology biotech, the governance signal here is at least as important as the personnel detail.

Why is Richard Hughes replacing Shaun Chilton as Avacta Therapeutics non-executive chairman?

Richard Hughes is not an outside hire parachuted in to steady the ship. He joined the Avacta Therapeutics board only in May 2025 alongside fellow non-executive director David Bryant, so the elevation to chair reads as planned succession rather than a reactive move. Richard Hughes brings more than 30 years of UK capital markets experience covering initial public offerings, equity fundraising, and mergers and acquisitions, and he is the founder of financial services group Zeus Capital. He was also a founder shareholder and director of boohoo.com and a majority shareholder in Crawford Healthcare before its 2018 sale. That profile matters because it tilts the chair role toward financing and transaction fluency rather than pure scientific stewardship.

Shaun Chilton, who took the chair in June 2024 after Eliot Forster stepped down, carried the company through its hardest strategic pivot. As the former chief executive officer of Clinigen Group, which he sold to Triton Partners for around £1.3 billion in 2022, Shaun Chilton anchored the board during the disposal of non-core assets and the repositioning of Avacta Therapeutics as a pure-play therapeutics business. His decision to remain as an adviser to the chief executive officer rather than make a clean exit suggests the board wants institutional memory retained through the next phase, while freeing the chair seat for someone whose skill set maps to capital raising and deal structuring. The competitive read is straightforward. A small-cap clinical biotech that intends to fund expensive late-stage oncology trials and negotiate licensing deals benefits from a chair who has spent a career on the financing side of the table.

What does the new deputy chairman appointment signal about Avacta Therapeutics pharma partnering ambitions?

The quieter but arguably more telling line in the announcement is the creation of a deputy chairman role earmarked for someone with global biotechnology expertise. Layering in a deputy with sector depth, on top of a chair drawn from capital markets, looks like a deliberate attempt to balance the boardroom across two competencies that a partnering-stage biotech needs in equal measure: the financial nous to raise and deploy capital, and the scientific and commercial credibility to sit opposite large pharmaceutical counterparties.

This is a board being engineered for negotiation. Avacta Therapeutics has been explicit that it is engaging potential pharmaceutical partners for its pre|CISION oncology candidates, and partnering discussions with global drug majors are won or lost on the quality of the people in the room. A deputy chairman with a recognised biotech track record gives the company a senior figure who can speak the language of partner due diligence and validate the science to a counterparty’s satisfaction. The second-order implication is that management is signalling confidence that its lead assets are far enough along to attract that kind of conversation. Boards do not usually retool for deal-making unless they believe deals are realistically in view.

How does the Avacta Therapeutics board reshuffle fit the pure-play oncology biotech transition?

The board change is the latest step in a multi-year reshaping that has steadily removed legacy diagnostics weight and concentrated the company around its pre|CISION platform. That platform is built on fibroblast activation protein, an enzyme upregulated in most solid tumours but largely absent from healthy tissue, which Avacta Therapeutics uses to activate its peptide drug conjugates inside the tumour microenvironment while sparing normal cells. The lead programme, AVA6000, is a pre|CISION-enabled form of doxorubicin, and a second candidate, AVA6103, pairs the platform with the topoisomerase inhibitor exatecan.

Reconstituting the board around financing and partnering competence is consistent with where a company sits when its science is maturing but its balance sheet still depends on external capital. The execution implication is that Avacta Therapeutics is positioning governance to support either a licensing transaction or a larger funding round, or both. There is also a continuity benefit worth noting. By retaining Shaun Chilton as an adviser and promoting an existing director rather than importing a stranger, the company avoids the disruption that an outside chair appointment can bring at a delicate moment. The risk attached to that approach is reduced fresh challenge at the top, since a board that promotes from within can drift toward consensus. Adding an external deputy chairman with global biotech standing is the obvious counterweight, provided the eventual appointee is genuinely independent in voice as well as title.

Why does the Avacta Therapeutics governance change matter with AVCT shares near a 52-week high?

Market context sharpens the significance of the timing. AVCT shares have traded in the low-to-mid 80s pence in recent sessions, against a 52-week range running from roughly 26p at the low to around 92p at the high, leaving the stock near the top of its annual band and broadly tripled from its trough. Market capitalisation sits in the region of £340m to £365m, and the recent recovery follows a long stretch in which the shares spent much of 2025 mired in the 30p to 55p zone. Analyst views are split, with consensus price targets ranging from levels well below the current price to estimates above 100p, reflecting the binary nature of clinical-stage biotech valuation.

A board change is rarely a share-price catalyst in its own right. What matters is whether the market reads it as preparation for value-creating events. Announcing a chair with deal-making pedigree and a deputy with biotech weight, while the equity sits near a 52-week high, frames the move as offensive rather than defensive. That alignment between governance signalling and a firming share price is the kind of context an investor should weigh, without over-reading a single corporate-governance release. Short-term price action around the announcement should not be treated as a verdict on the strategy.

What execution risks face Avacta Therapeutics as it advances pre|CISION oncology candidates toward partnering?

The risks are the familiar ones of clinical-stage oncology, and a stronger board does not neutralise them. Trial data for AVA6000 and AVA6103 must continue to read out favourably, because a single disappointing dataset can compress a biotech valuation faster than any boardroom improvement can offset. Partnering ambition also carries its own hazard. A company that publicly signals it is seeking pharmaceutical partners places pressure on itself to deliver a deal on acceptable terms, and a partnering process that drifts without a transaction can sour sentiment in a thinly traded AIM name.

Funding is the second pressure point. Late-stage oncology development is capital-intensive, and a chair drawn from capital markets is useful precisely because further fundraising is a realistic prospect, which in turn raises the question of dilution for existing holders. The governance transition should be judged on outcomes over the coming year: whether the new structure converts into a partnering agreement, a financing on favourable terms, or clinical progress that justifies the share price sitting near its highs. Until then, the board reshuffle is best read as a statement of intent from a company that believes its inflection point is approaching, not as confirmation that it has arrived.

Key takeaways on what the Avacta Therapeutics board change means for the company, its peers, and the sector

• Richard Hughes moves from non-executive director to non-executive chairman immediately after the 22 June 2026 AGM, signalling planned succession rather than a reactive appointment.
• Shaun Chilton steps down from the board but stays as an adviser to the chief executive officer, preserving institutional memory through the next strategic phase.
• The new chair’s capital markets and transaction background tilts board capability toward financing and deal-making, the precise skills a partnering-stage biotech needs.
• A planned deputy chairman with global biotechnology expertise points to a board being engineered for credibility opposite large pharmaceutical counterparties.
• The dual appointment structure balances financial fluency with scientific and commercial weight, a deliberate split for a company chasing both capital and partnerships.
• The reshuffle caps a multi-year transition from a diversified group into a pure-play oncology biotech built around the pre|CISION platform and lead assets AVA6000 and AVA6103.
• AVCT shares sit near the top of a 52-week range of roughly 26p to 92p, framing the governance move as offensive rather than defensive.
• Promoting from within reduces disruption but risks weaker boardroom challenge, making the independence of the incoming deputy chairman important.
• Execution risk remains concentrated in clinical readouts, partnering delivery, and the dilution that further fundraising could bring.
• The board should be judged on whether the new structure converts into a partnering deal, favourable financing, or clinical progress over the next twelve months.